Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

KOD - Kodiak Sciences Inc. So'nggi Yangiliklar | Finranks

Home

KOD

K

Kodiak Sciences Inc. (KOD)

NGM – Real vaqt narxi. Valyuta: USD

37.00

-2.76 (-6.94%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

37.46

+0.46 (1.24%)

Bozordan keyin: Mar 27, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate

KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate

Kodiak Sciences rallies 75% as phase III GLOW2 data show Zenkuda's strong efficacy, safety and risk reduction in diabetic retinopathy patients.

Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

Investors appear to be responding to both the strength of the data and the possibility of a faster path toward a biologics license application, or BLA. Here's what investors need to know.

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

Shares of drug developer Kodiak Sciences jumped 52% before the bell on Thursday after its experimental drug met the main goal in a ‌late-stage study in patients with diabetes-related eye damage.

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p

Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing

Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing

Acquired 386,000 shares of Kodiak Sciences (NASDAQ: KOD); estimated transaction value of $7.90 million based on quarterly average pricing Quarter-end Kodiak Sciences position value rose by $19.49 million, reflecting both trading and price movement Transaction represented a 1.73% increase relative to fund 13F AUM Boxer Capital Management, LLC held 1,136,000 Kodiak Sciences shares valued at $31.76 million after the trade Kodiak Sciences position now represents 6.95% of 13F AUM, which places it outside the fund's top five holdings

Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy

Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy

Baker Bros. Advisors increased its Kodiak Sciences stake by 2,608,696 shares; the estimated trade size was $53.42 million.

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead

Connecticut-based Braidwell bought 2,072,788 shares in Kodiak Sciences in the fourth quarter. The quarter-end position value increased by $57.96 million, reflecting the establishment of the new position.

Videolar

The Big 3: GOOGL, KOD, FTK

Press-relizlar

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026.

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

PALO ALTO, Calif. , Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $23.00 per share.

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock

PALO ALTO, Calif. , Dec. 16, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the pricing of an upsized underwritten public offering of 6,956,522 shares of its common stock at a price to the public of $23.00 per share.